Publications by authors named "Pascal Turlure"

Claim this Profile
A
Allogeneic hematopoietic stem cell transplantation in patients with germ line DDX41 mutated myeloid malignancies.
Michael Loschi, Marie-Charlotte Villy, Jacques-Emmanuel Galimard, Marie-Mathilde Auboiroux, Nathalie Gachard, Pascal Turlure

Blood Adv· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Thiotepa-busulfan-fludarabine compared to clofarabine-based conditioning for haploidentical transplant with posttransplant cyclophosphamide in patients with myeloid malignancies: a retrospective study from the SFGM-TC.
Maxime Jullien, Eolia Brissot, Etienne Daguindau, Michael Loschi, Ali Bazarbachi, Pascal Turlure

Bone Marrow Transplant· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Myeloid neoplasms risks for germline DDX41 pathogenic variants carriers.
Marie-Charlotte Villy, Youenn Drouet, Lise Larcher, Yoann Vial, Benjamin Dauriat, Pascal Turlure

Eur J Hum Genet· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Age-adapted chemotherapy and MRD-oriented transplant for Ph-negative acute lymphoblastic leukemia: the GRAALL-2014 trial.
Nicolas Boissel, Sylvie Chevret, Françoise Rigal-Huguet, Thibaut Tl Leguay, Mathilde Hunault, Pascal Turlure

Blood· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Acute graft-versus-host disease therapy: Which third line treatment after steroids and ruxolitinib? (SFGM-TC)].
Tereza Coman, Fabio Andreozzi, Jaques-Olivier Bay, Jérôme Cornillon, Thierry Guillaume, Pascal Turlure

Bull Cancer· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcome of patients with accelerated and blast-phase myeloproliferative neoplasms not eligible for intensive chemotherapy or allogeneic hematopoietic cell transplantation treated by azacitidine alone or in combination-A FIM study.
Corentin Orvain, Suzanne Tavitian, Clémence Mediavilla, Françoise Boyer, Alberto Santagostino, Pascal Turlure

Hemasphere· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Allogeneic Hematopoietic Stem Cell Transplantation for Elderly Acute Lymphoblastic Leukemia Patients: A Registry Study From the Société Francophone de Greffe de Moelle et Thérapie Cellulaire (SFGM-TC).
Yves Chalandon, Raynier Devillier, Ariane Boumendil, Stephanie Nguyen, Claude-Eric Bulabois, Pascal Turlure

Am J Hematol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intermediate-Dose Cytarabine as Postinduction AML Therapy.
Mathilde Hunault, Cécile Pautas, Sarah Bertoli, Pierre-Yves Dumas, Emmanuel Raffoux, Pascal Turlure

NEJM Evid· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FLT3 ligand kinetic profile predicts response to treatment in patients with high-risk myelodysplastic syndrome/ chronic myelomonocytic leukemia receiving CPX-351: a study from the Groupe Francophone des Myélodysplasies.
Pierre Peterlin, Joëlle Gaschet, Pascal Turlure, Marie-Pierre Gourin, Pierre-Yves Dumas

Haematologica· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Ruxolitinib stopped before transplantation does not induce cytokine release in myelofibrosis.
Sara Villar, Emmanuel Curis, Marie-Hélène Schlageter, Nelly Bosselut, Amandine Charbonnier, Pascal Turlure

Cancer Immunol Immunother· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Remdesivir for the Treatment of Human Coronavirus OC43 Encephalitis.
Jacques Fourgeaud, Pascal Turlure, Marine Dupont, Nicolas Veyrenche, Clémence Busquet

J Med Virol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Place of hematopoietic stem cell transplantation for very high risk acute myeloblastic leukemia and myelodysplastic syndromes (SFGM-TC)].
Clémence Mediavilla, Maud D'Aveni, Anne Huynh, Magalie Joris, Stravoula Masouridi-Levrat, Pascal Turlure

Bull Cancer· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inotuzumab Ozogamicin and Low-Intensity Chemotherapy in Older Patients With Newly Diagnosed CD22 Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia.
Patrice Chevallier, Thibaut Leguay, Marc Delord, Cyril Salek, Rathana Kim, Pascal Turlure

J Clin Oncol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Follow-Up of the Prospective Randomized AATT Study (Autologous or Allogeneic Transplantation in Patients With Peripheral T-Cell Lymphoma).
Olivier Tournilhac, Bettina Altmann, Birte Friedrichs, Kamal Bouabdallah, Mathieu Leclerc, Pascal Turlure

J Clin Oncol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PD-1 blockade and allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma, a matter of time: a national study on behalf of the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire.
Eleonore Kaphan, Francois Bettega, Nicolas Vallet, Nathalie Fegueux, Marie Robin, Pascal Turlure

Haematologica· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nilotinib with or without cytarabine for Philadelphia-positive acute lymphoblastic leukemia.
Yves Chalandon, Philippe Rousselot, Sylvie Chevret, Jean-Michel Cayuela, Rathana Kim, Pascal Turlure

Blood· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hypomethylating agent monotherapy in core binding factor acute myeloid leukemia: a French multicentric retrospective study.
Ludovic Gabellier, Pierre Peterlin, Sylvain Thepot, Yosr Hicheri, Franciane Paul, Pascal Turlure

Ann Hematol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pneumocystis Pneumonia After Allogeneic Hematopoietic Cell Transplantation: A Case-Control Study on Epidemiology and Risk Factors on Behalf of the Infectious Diseases Working Party of the European Society for Blood and Marrow Transplantation.
Christine Robin, Catherine Cordonnier, Gloria Tridello, Nina Knelange, Alienor Xhaard, Pascal Turlure

Transplant Cell Ther· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bone marrow graft versus peripheral blood graft in haploidentical hematopoietic stem cells transplantation: a retrospective analysis in1344 patients of SFGM-TC registry.
Claire Lacan, Jérôme Lambert, Edouard Forcade, Marie Robin, Patrice Chevallier, Pascal Turlure

J Hematol Oncol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Allogeneic hematopoietic stem cell transplantation for adults with therapy-related acute myeloid leukaemia: a retrospective multicentre study on behalf of the SFGM-TC.
Gaëlle Rey, Elisabeth Daguenet, Paul Bonjean, Raynier Devillier, Nathalie Fegueux, Pascal Turlure

Bone Marrow Transplant· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CPX-351 in higher risk myelodysplastic syndrome and chronic myelomonocytic leukaemia: a multicentre, single-arm, phase 2 study.
Pierre Peterlin, Yannick Le Bris, Pascal Turlure, Patrice Chevallier, Audrey Ménard

Lancet Haematol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcome after allogeneic stem cell transplantation with haploidentical versus HLA-matched donors in patients with higher-risk MDS.
Claire Michel, Marie Robin, Stephane Morisset, Didier Blaise, Johan Maertens, Pascal Turlure

Bone Marrow Transplant· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nilotinib efficacy and safety as salvage treatment following imatinib intolerance and/or inefficacy in steroid refractory chronic graft-versus-host-disease (SR-cGVHD): a prospective, multicenter, phase II study on behalf of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC).
Micha Srour, Tamim Alsuliman, Julien Labreuche, Claude-Eric Bulabois, Patrice Chevallier, Pascal Turlure

Bone Marrow Transplant· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Post-transplant cyclophosphamide in acute leukemia patients receiving more than 5/10 HLA-mismatched allogeneic hematopoietic cell transplantation from related donors: A study on behalf of the ALWP of the EBMT.
Michele Wieczorek, Myriam Labopin, Luca Castagna, Eolia Brissot, Gerard Socié, Pascal Turlure

Am J Hematol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hereditary predisposition to malignant myeloid hemopathies: Caution in use of saliva and guideline based on our experience.
Alexandre Perani, Sylvie Bourthoumieu, David Rizzo, Jasmine Chauzeix, Benjamin Dauriat, Pascal Turlure

Front Oncol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis